CD274 and neoplasm: PD‐1/PD‐L1 inhibitor kills tumor cells, which express human leukocyte antigen‐1 (HLA‐1), by increasing T cell activity; however, HLA‐1 negative tumor cells can escape from immunotherapy through “missing self”.14